Antithrombotic Drug Therapy for IgA Nephropathy: A Meta Analysis of Randomized Controlled Trials

• Published in: Internal Medicine Vol. 50; no. 21; pp. 2503 - 2510
• Main Authors: Liu, Xiu-Juan, Geng, Yan-Qiu, Xin, Shao-Nan, Huang, Guo-Ming, Tu, Xiao-Wen, Ding, Zhong-Ru, Chen, Xiang-Mei
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.01.2011
• Subjects: Antithrombotic agents; Benzazepines - therapeutic use; Fibrinolytic Agents - therapeutic use; Glomerulonephritis; Glomerulonephritis, IGA - drug therapy; Glomerulonephritis, IGA - epidemiology; Glomerulonephritis, IGA - metabolism; Humans; IgA nephropathy; Meta analysis; Proteinuria - drug therapy; Proteinuria - epidemiology; Proteinuria - metabolism; Randomized Controlled Trials as Topic - methods
• ISSN: 0918-2918; 1349-7235; 1349-7235
• DOI: 10.2169/internalmedicine.50.5971

Background Antithrombotic agents, including antiplatelet agents, anticoagulants and thrombolysis agents, have been widely used in the management of immunoglobulin A (IgA) nephropathy in Chinese and Japanese populations. To systematically evaluate the effects of antithrombotic agents for IgA nephropathy. Methods Data sources consisted of MEDLINE, EMBASE, the Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Periodicals Databases (CNKI) and Japana Centra Revuo Medicina (http://www.jamas.gr.jp) up to April 5, 2011. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function. Results Six articles met the predetermined inclusion criteria. Antithrombotic agents showed statistically significant effects on proteinuria (p<0.0001) but not on the protection of renal function (p=0.07). The pooled risk ratio for proteinuria was 0.53, [95% confidence intervals (CI): 0.41-0.68; I2=0%] and for renal function it was 0.42 (95% CI 0.17-1.06; I2=72%). Subgroup analysis showed that dipyridamole was beneficial for proteinuria (p=0.0003) but had no significant effects on protecting renal function. Urokinase had statistically significant effects both on the reduction of proteinuria (p=0.0005) and protecting renal function (p<0.00001) when compared with the control group. Conclusion Antithrombotic agents had statistically significant effects on the reduction of proteinuria but not on the protection of renal function in patients with IgAN. Urokinase had statistically significant effects both on the reduction of proteinuria and on protecting renal function. Urokinase was shown to be a promising medication and should be investigated further.